(HLNE) Hamilton Lane - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4074971064
Stock: Private Equity, Venture Capital, Funds, Credit
Total Rating 39
Risk 82
Buy Signal -0.77
| Risk 5d forecast | |
|---|---|
| Volatility | 36.2% |
| Relative Tail Risk | 0.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.73 |
| Alpha | -51.98 |
| Character TTM | |
|---|---|
| Beta | 1.296 |
| Beta Downside | 1.507 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.41% |
| CAGR/Max DD | 0.28 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: HLNE Hamilton Lane March 04, 2026
Hamilton Lane Inc. is a private equity and venture capital firm. It specializes in various stages of company growth, from early-stage ventures to mature companies, and employs diverse investment strategies, including direct credit and fund-of-funds.
The firm invests across a broad range of sectors, including disruptive technologies, healthcare, energy, and real estate. Its investment focus spans global regions, with a preference for investments between $0.25 million and $100 million, often seeking majority stakes. Asset management firms typically earn fees based on assets under management (AUM).
To deepen your understanding of HLNEs financial performance, consider exploring its detailed financials on ValueRay.
Headlines to watch out for
- Global private markets fundraising impacts asset under management growth
- Management fees from diverse strategies drive revenue stability
- Performance fees fluctuate with investment realization and market cycles
- Interest rate changes influence private credit fund performance
- Regulatory scrutiny on private equity fees poses potential risk
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 233.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -0.76 > 1.0 |
| NWC/Revenue: 32.66% < 20% (prev 37.26%; Δ -4.60% < -1%) |
| CFO/TA 0.17 > 3% & CFO 363.5m > Net Income 233.5m |
| Net Debt (19.7m) to EBITDA (446.2m): 0.04 < 3 |
| Current Ratio: 1.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.5m) vs 12m ago 0.08% < -2% |
| Gross Margin: 69.23% > 18% (prev 0.73%; Δ 6.85k% > 0.5%) |
| Asset Turnover: 40.59% > 50% (prev 42.94%; Δ -2.36% > 0%) |
| Interest Coverage Ratio: 28.74 > 6 (EBITDA TTM 446.2m / Interest Expense TTM 15.2m) |
Altman Z'' 3.88
| A: 0.11 (Total Current Assets 567.6m - Total Current Liabilities 318.2m) / Total Assets 2.17b |
| B: 0.26 (Retained Earnings 571.0m / Total Assets 2.17b) |
| C: 0.23 (EBIT TTM 436.5m / Avg Total Assets 1.88b) |
| D: 0.68 (Book Value of Equity 572.2m / Total Liabilities 844.8m) |
| Altman-Z'' Score: 3.88 = AA |
Beneish M -2.74
| DSRI: 1.18 (Receivables 207.1m/157.0m, Revenue 763.4m/683.3m) |
| GMI: 1.06 (GM 69.23% / 73.20%) |
| AQI: 1.10 (AQ_t 0.69 / AQ_t-1 0.63) |
| SGI: 1.12 (Revenue 763.4m / 683.3m) |
| TATA: -0.06 (NI 233.5m - CFO 363.5m) / TA 2.17b) |
| Beneish M-Score: -2.74 (Cap -4..+1) = A |
What is the price of HLNE shares?
As of March 25, 2026, the stock is trading at USD 102.01 with a total of 873,432 shares traded.
Over the past week, the price has changed by +5.56%, over one month by +1.41%, over three months by -25.92% and over the past year by -33.44%.
Over the past week, the price has changed by +5.56%, over one month by +1.41%, over three months by -25.92% and over the past year by -33.44%.
Is HLNE a buy, sell or hold?
Hamilton Lane has received a consensus analysts rating of 2.83.
Therefor, it is recommend to hold HLNE.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HLNE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 172.9 | 69.5% |
| Analysts Target Price | 172.9 | 69.5% |
HLNE Fundamental Data Overview March 24, 2026
P/E Trailing = 17.7522
P/E Forward = 15.7978
P/S = 7.2799
P/B = 4.9873
P/EG = 1.39
Revenue TTM = 763.4m USD
EBIT TTM = 436.5m USD
EBITDA TTM = 446.2m USD
Long Term Debt = 279.5m USD (from longTermDebt, last quarter)
Short Term Debt = 21.7m USD (from shortTermDebt, last fiscal year)
Debt = 359.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.58b USD (5.56b + Debt 359.8m - CCE 340.2m)
Interest Coverage Ratio = 28.74 (Ebit TTM 436.5m / Interest Expense TTM 15.2m)
EV/FCF = 15.67x (Enterprise Value 5.58b / FCF TTM 356.0m)
FCF Yield = 6.38% (FCF TTM 356.0m / Enterprise Value 5.58b)
FCF Margin = 46.63% (FCF TTM 356.0m / Revenue TTM 763.4m)
Net Margin = 30.59% (Net Income TTM 233.5m / Revenue TTM 763.4m)
Gross Margin = 69.23% ((Revenue TTM 763.4m - Cost of Revenue TTM 234.9m) / Revenue TTM)
Gross Margin QoQ = 69.34% (prev 70.80%)
Tobins Q-Ratio = 2.57 (Enterprise Value 5.58b / Total Assets 2.17b)
Interest Expense / Debt = 1.02% (Interest Expense 3.69m / Debt 359.8m)
Taxrate = 22.70% (27.3m / 120.0m)
NOPAT = 337.4m (EBIT 436.5m * (1 - 22.70%))
Current Ratio = 1.78 (Total Current Assets 567.6m / Total Current Liabilities 318.2m)
Debt / Equity = 0.41 (Debt 359.8m / totalStockholderEquity, last quarter 877.4m)
Debt / EBITDA = 0.04 (Net Debt 19.7m / EBITDA 446.2m)
Debt / FCF = 0.06 (Net Debt 19.7m / FCF TTM 356.0m)
Total Stockholder Equity = 794.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.41% (Net Income 233.5m / Total Assets 2.17b)
RoE = 29.38% (Net Income TTM 233.5m / Total Stockholder Equity 794.8m)
RoCE = 40.63% (EBIT 436.5m / Capital Employed (Equity 794.8m + L.T.Debt 279.5m))
RoIC = 31.22% (NOPAT 337.4m / Invested Capital 1.08b)
WACC = 9.95% (E(5.56b)/V(5.92b) * Re(10.54%) + D(359.8m)/V(5.92b) * Rd(1.02%) * (1-Tc(0.23)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.47%
[DCF] Terminal Value 73.68% ; FCFF base≈322.7m ; Y1≈364.4m ; Y5≈492.7m
[DCF] Fair Price = 140.0 (EV 6.17b - Net Debt 19.7m = Equity 6.15b / Shares 43.9m; r=9.95% [WACC]; 5y FCF grow 14.98% → 3.0% )
EPS Correlation: 67.23 | EPS CAGR: 15.94% | SUE: 1.09 | # QB: 3
Revenue Correlation: 77.56 | Revenue CAGR: 19.79% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.48 | Chg7d=+0.000 | Chg30d=+0.033 | Revisions Net=+3 | Analysts=7
EPS next Year (2027-03-31): EPS=6.41 | Chg7d=+0.000 | Chg30d=+0.106 | Revisions Net=+6 | Growth EPS=+10.6% | Growth Revenue=+16.8%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 10.5% - Earnings Yield 5.6%)
[Growth] Growth Spread = +19.1% (Analyst 24.0% - Implied 4.9%)
P/E Forward = 15.7978
P/S = 7.2799
P/B = 4.9873
P/EG = 1.39
Revenue TTM = 763.4m USD
EBIT TTM = 436.5m USD
EBITDA TTM = 446.2m USD
Long Term Debt = 279.5m USD (from longTermDebt, last quarter)
Short Term Debt = 21.7m USD (from shortTermDebt, last fiscal year)
Debt = 359.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.58b USD (5.56b + Debt 359.8m - CCE 340.2m)
Interest Coverage Ratio = 28.74 (Ebit TTM 436.5m / Interest Expense TTM 15.2m)
EV/FCF = 15.67x (Enterprise Value 5.58b / FCF TTM 356.0m)
FCF Yield = 6.38% (FCF TTM 356.0m / Enterprise Value 5.58b)
FCF Margin = 46.63% (FCF TTM 356.0m / Revenue TTM 763.4m)
Net Margin = 30.59% (Net Income TTM 233.5m / Revenue TTM 763.4m)
Gross Margin = 69.23% ((Revenue TTM 763.4m - Cost of Revenue TTM 234.9m) / Revenue TTM)
Gross Margin QoQ = 69.34% (prev 70.80%)
Tobins Q-Ratio = 2.57 (Enterprise Value 5.58b / Total Assets 2.17b)
Interest Expense / Debt = 1.02% (Interest Expense 3.69m / Debt 359.8m)
Taxrate = 22.70% (27.3m / 120.0m)
NOPAT = 337.4m (EBIT 436.5m * (1 - 22.70%))
Current Ratio = 1.78 (Total Current Assets 567.6m / Total Current Liabilities 318.2m)
Debt / Equity = 0.41 (Debt 359.8m / totalStockholderEquity, last quarter 877.4m)
Debt / EBITDA = 0.04 (Net Debt 19.7m / EBITDA 446.2m)
Debt / FCF = 0.06 (Net Debt 19.7m / FCF TTM 356.0m)
Total Stockholder Equity = 794.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.41% (Net Income 233.5m / Total Assets 2.17b)
RoE = 29.38% (Net Income TTM 233.5m / Total Stockholder Equity 794.8m)
RoCE = 40.63% (EBIT 436.5m / Capital Employed (Equity 794.8m + L.T.Debt 279.5m))
RoIC = 31.22% (NOPAT 337.4m / Invested Capital 1.08b)
WACC = 9.95% (E(5.56b)/V(5.92b) * Re(10.54%) + D(359.8m)/V(5.92b) * Rd(1.02%) * (1-Tc(0.23)))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.47%
[DCF] Terminal Value 73.68% ; FCFF base≈322.7m ; Y1≈364.4m ; Y5≈492.7m
[DCF] Fair Price = 140.0 (EV 6.17b - Net Debt 19.7m = Equity 6.15b / Shares 43.9m; r=9.95% [WACC]; 5y FCF grow 14.98% → 3.0% )
EPS Correlation: 67.23 | EPS CAGR: 15.94% | SUE: 1.09 | # QB: 3
Revenue Correlation: 77.56 | Revenue CAGR: 19.79% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.48 | Chg7d=+0.000 | Chg30d=+0.033 | Revisions Net=+3 | Analysts=7
EPS next Year (2027-03-31): EPS=6.41 | Chg7d=+0.000 | Chg30d=+0.106 | Revisions Net=+6 | Growth EPS=+10.6% | Growth Revenue=+16.8%
[Analyst] Revisions Ratio: +0.60 (4 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.9% (Discount Rate 10.5% - Earnings Yield 5.6%)
[Growth] Growth Spread = +19.1% (Analyst 24.0% - Implied 4.9%)